头部和部状细胞癌患者的尼沃卢马布耐药性以及未来的前景
Karolina Buchajska1,2, Anna Mydlak2, Jakub Zwoliński2
1Medical University of Warsaw, Faculty of Medicine, English Division, Warszawa, Poland.
Contemporary oncology (Poznan, Poland)
|May 7, 2025
概括
头癌 (HNC) 正在增加,对尼沃卢马布免疫疗法的耐药性是一个主要障碍. 这篇评论探讨了瘤因素,瘤微环境和免疫检查点如何驱动这种抵抗,从而需要新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症研究 癌症研究
背景情况:
- 在全球范围内,头癌 (HNC) 的发病率正在增加.
- 对像尼沃卢马布这样的免疫疗法的耐药性在HNC管理中构成了重大临床挑战.
研究的目的:
- 系统地审查HNC中尼沃卢马布耐药性的基础机制.
- 为了确定内在的瘤因素,瘤微环境 (TME) 特性和免疫检查点调节失调有助于抵抗.
主要方法:
- 系统的文献审查.
- 分析内在瘤因素 (例如突变,MYC放大).
- 评估TME组成 (例如,免疫抑制细胞) 和免疫检查点通路 (例如PD-L1,TIM-3,LAG-3).
主要成果:
- 内在瘤因素,包括抗原呈现受损和MYC放大,通过重塑TME促进免疫逃避.
- 一种免疫抑制性TME,其特征是瘤相关的巨细胞和髓状细胞衍生的抑制细胞,降低了nivolumab的疗效.
- 癌细胞利用PD-L1,TIM-3和LAG-3等免疫检查点来逃避免疫监测.
结论:
- HNC中的尼沃卢马布耐药性是多因素的,涉及瘤内在性质,TME调节和免疫检查点激活.
- 识别MYC放大和PD-L1表达等生物标志物对于个性化HNC治疗至关重要.
- 迫切需要全面的治疗策略来克服尼沃卢马布耐药性并改善患者的治疗结果.
相关概念视频
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:27Tumor Immunotherapy
401
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
401
01:30Cancer Vaccines
251
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
251
02:49Cancer Therapies
7.4K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
137
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
137